Harmony Biosciences Holdings (HRMY) Earnings Analysis
Harmony Biosciences Holdings (HRMY) has no confirmed upcoming earnings date. Last quarter (2026-05-07) it missed with EPS 0.55 USD vs 0.76 USD est (-27.6%). It has beaten estimates in 0/1 recent quarters (0%). Trailing P/E 13.83.
Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades
When does HRMY next report earnings?
No confirmed upcoming earnings date is currently scheduled for HRMY. This page updates as the calendar is published.
HRMY earnings history — beats and misses
| Quarter (report date) | EPS actual | EPS est. | Surprise | Result |
|---|---|---|---|---|
| 2026-05-07 | 0.55 USD | 0.76 USD | -27.6% | Miss |
Beat rate: 0/1 (0%) over reported quarters with consensus data.
HRMY valuation and analyst view
| Trailing P/E | 13.83 |
|---|---|
| Trailing EPS | 2.518 USD |
| Price / book | 2.21 |
| Dividend yield | 0.00% |
| Market cap | 2.07B |
| Analyst consensus | Buy (8 buy / 3 hold / 2 sell) |
| Avg price target | 36 USD |
Related research pages
Frequently asked questions
When is Harmony Biosciences Holdings (HRMY)'s next earnings date?
No confirmed upcoming earnings date is currently scheduled for HRMY. This page updates as the calendar is published.
Did HRMY beat earnings last quarter?
In its 2026-05-07 report, HRMY posted EPS of 0.55 USD versus a 0.76 USD estimate — a miss of 27.6%.
What is HRMY's earnings track record?
Over the last 1 reported quarters with consensus data, HRMY beat estimates 0 times (0%).
What is HRMY's current P/E ratio and EPS?
HRMY trades at a trailing P/E of 13.83 on trailing EPS of 2.518460175589157 USD.
What do analysts rate HRMY?
Analyst consensus is "Buy" across 13 ratings (0 strong buy, 8 buy, 3 hold, 2 sell, 0 strong sell). Average 12-month price target: 36 USD.